Study of CTX-471 as a Monotherapy or in Combination With Pembrolizumab in Patients Post PD-1/PD-L1 Inhibitors in Metastatic or Locally Advanced Malignancies
← catalyst calendarSponsored by Compass Therapeutics (industry) · CMPX — their whole pipeline →. With IQVIA Pty Ltd, Merck, Sharp & Dohme, LLC, Rahway, NJ USA.
Phase
Phase 1
Status
Completed
Study type
Interventional
Design
Non randomized · None · Treatment
Enrollment
100actual
Sites
10
Country
United States
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2019-05-17 | actual | When the study began enrolling |
| Primary completion | 2025-05-21 | actual | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | 2025-05-21 | actual | The whole study's end, after follow-up |
| First posted | 2019-03-19 | actual | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2026-04-17 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Conditions
- Locally Advanced Solid Tumor
- Metastatic Cancer
- Non-small Cell Lung Cancer
- Small Cell Lung Cancer
- Mesothelioma
- Melanoma
- Head and Neck Cancer
Interventions
- Drug: CTX-471
- Drug: Pembrolizumab (KEYTRUDA®) — also filed as KEYTRUDA®
Primary outcome
what the primary-completion date above is the date OFNumber of participants with dose limiting toxicities (DLTs), treatment-emergent adverse events (TEAEs), and/or changes in clinical laboratory abnormalities
measured From first dose of CTX-471 (Week 1 Day 1) until 60 days after the last CTX-471 injection (up to 2 years)
Publications
- PMID 38172595 — linked by the registry
Linked on the registry record. A “linked by the registry” entry is NLM's own automated PubMed match, not a claim by the sponsor that the paper reports this study.
Permalink · CMPX's whole pipeline · Catalyst calendar · Every registered study · What changed